Weekly Cisplatin plus Capecitabine in Metastatic Breast Cancer Patients Heavily Pretreated with both Anthracycline and Taxanes

Donadio, Michela; Ardine, Mara; Berruti, Alfredo; Beano, Alessandra; Bottini, Alberto; Mistrangelo, Marinella; Bonardi, S; Castiglione, F.; Generali, Daniele; Polimeni, Maria Antonia; Bretti, S.; Alabiso, Oscar; Bertetto, Oscar

doi:10.1159/000089995

Cited by 12 publications

(12 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Altogether, nausea/vomiting were the most common non-hematological toxicities and the incidence in our study appeared to be higher than previous reports. 18,19 Nevertheless, the majority of these events were presented as nausea only, with much less patients complaining about vomiting. Furthermore, most nausea/vomiting events occurred in the first cycle of XP regimen, and decreased with strengthened antiemesis therapy thereafter.…”

Section: Discussionmentioning

confidence: 99%

“…12,13 Besides, several studies evaluating the association of cisplatin and continuous infusion 5-FU have shown response rate ranging 11-48% in second-or third-line treatment, [14][15][16][17] and 62/ in first-line approach. 14 Additionally, 2 prospective trials 18,19 have obtained interesting results with the combination of cisplatin and capecitabine in unselected MBC patients pretreated with anthracyclines and/or taxanes, indicating an ORR range of 35.9-51.5%, PFS of 5.2-6.3 months and OS of 10.9-11.5 months.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

A phase II study of capecitabine plus cisplatin in metastatic triple-negative breast cancer patients pretreated with anthracyclines and taxanes

Zhang

et al. 2015

Cancer Biology & Therapy

View full text Add to dashboard Cite

Background: Cisplatin is an effective agent for triple-negative breast cancer (TNBC) and synergistic activity between cisplatin and capecitabine has been demonstrated by in vitro and in vivo studies. This study was designed as a prospective clinical trial to evaluate the efficacy and safety of capecitabine plus cisplatin (XP) regimen in metastatic TNBC patients pretreated with anthracyclines and taxanes. Patients and Methods: Thirty-three patients with metastatic TNBC who had anthracyclines and taxanes as prior therapy were treated with capecitabine 2000 mg/m 2 orally on day 1 through 14 plus cisplatin 75mg/m 2 intravenously on day 1 of a 21-day cycle, followed by capecitabine maintenance medications after a maximum of 6 cycles. The primary end point was objective response rate (ORR) and the secondary end points included progression-free survival (PFS), overall survival (OS) and toxicity profiles. Results: A total of 162 cycles was given. ORR was 63.6%. Median PFS was 8.2 (95%CI: 4.8-11.6) months in the entire population and 10.8 (95%CI: 6.5-15.1) months in responding patients. Median OS was 17.8 (95%CI: 14.4-21.2) months in all enrolled patients and 25.8 (95%CI: 14.6-37.0) months in responding patients. Most adverse events were mild and manageable, with neutropenia and nausea/vomiting as the most common toxicities. Grade 3/4 toxicities included leukopenia (10, 30.3%), neutropenia (10, 30.3%), anemia (2, 6.1%), thrombocytopenia (1, 3.0%), nausea/vomiting (3, 9.1%), hand-foot syndrome (HFS; 1, 3.0%), and sensory neuropathy (1, 3.0%). Conclusions: Capecitabine plus cisplatin demonstrated an excellent activity and an acceptable safety profile in metastatic TNBC patients pretreated with anthracyclines and taxanes.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

A phase II study of capecitabine plus cisplatin in metastatic triple-negative breast cancer patients pretreated with anthracyclines and taxanes

Zhang

et al. 2015

Cancer Biology & Therapy

View full text Add to dashboard Cite

show abstract

“…Different schedules of the CapCisp combination for advanced breast carcinoma have been reported [18][19][20] . Donadio et al [18] reported an objective response rate of 35.9% (complete response 7.7%) and 10.9 months OS (16.5 months in responding cases) in 39 MBC patients pretreated with anthracycline and taxane with a regimen containing weekly Cisp and Cap.…”

Section: Discussionmentioning

confidence: 99%

“…Donadio et al [18] reported an objective response rate of 35.9% (complete response 7.7%) and 10.9 months OS (16.5 months in responding cases) in 39 MBC patients pretreated with anthracycline and taxane with a regimen containing weekly Cisp and Cap. The addition of epirubicin to Cisp and Cap (EXC regimen) as neoadjuvant chemotherapy in locally advanced or inflammatory breast carcinoma also improved the overall and complete response rates (74 and 13%) to the cost of chemotherapyinduced nausea/vomiting and hypercoagulable disorders [20] .…”

Section: Discussionmentioning

confidence: 99%

Capecitabine and Cisplatin Combination Is an Active and Well-Tolerated Doublet in the Treatment of Metastatic Breast Carcinoma Patients Pretreated with Anthracycline and Taxanes

Öksüzoğlu

Abalı²,

Hayran³

et al. 2008

Chemotherapy

View full text Add to dashboard Cite

Our aim was to evaluate the activity and toxicity of capecitabine and cisplatin (CapCisp) combination in anthracycline- and taxane-pretreated metastatic breast cancer patients. Thirty-three patients, 20–61 years of age (median 41), were included. They received Cap 2,000 mg/m² on days 1–14 and Cisp 60 mg/m² on day 1, repeated every 3 weeks. Twelve nonprogressive patients continued single-agent Cap therapy until progression or until intolerable toxicity after Cisp cessation. The disease control rate in 154 cycles was 81.8%: complete response 3.0% (n = 1), partial response 48.5% (n = 16) and stable disease 30.3% (n = 10). The median time to disease progression was 6.3 months (95% CI 3.8–8.8). The median overall survival was 11.5 months (95% CI 6.9–16.1). The only grade 3 toxicity was neutropenia, observed in 4 patients (12.1%). CapCisp has an encouraging anti-tumor activity with a low toxicity rate in anthracycline- and taxane-pretreated metastatic breast cancer patients.

show abstract

“…Median TTP was 5.2 months and median OS was 10.9 months. The dose-limiting toxicity for the regimen was leukopenia, while gastrointestinal discomfort was the most frequent cause of capecitabine reduction or delay [126]. When cisplatin was replaced with oxaliplatin, the RR was 32%.…”

Section: Experience With Combination Chemotherapymentioning

confidence: 99%

Platinum-Based Compounds for the Treatment of Metastatic Breast Cancer

Shamseddine¹,

Farhat²

2011

Chemotherapy

View full text Add to dashboard Cite

The role of platinum-based compounds (PBCs) in the treatment of metastatic breast cancer (MBC) has been extensively studied. As single agents, high response rates have been observed in first-line therapy, while results in pretreated patients were discouraging. Regimens containing cisplatin/carboplatin together with taxanes showed the highest efficacy and safety as both first-line and second-line therapy. When administered with vinorelbine, the combination was also active and well tolerated in anthracycline- and taxane-pretreated patients. Combining PBCs with etoposide or nucleoside analogues showed moderate activity, yet high toxicity in the case of etoposide. The overall results for the combination with anthracyclines were disappointing. Addition of trastuzumab to PBC combinations showed remarkable activity and good tolerability in patients with HER2/neu overexpression. The use of cisplatin or carboplatin alongside novel targeted therapeutics for patients with triple-negative MBC seems promising and is being further evaluated. The use of PBCs against MBC requires careful patient selection and combination with the right chemotherapeutic agent.

show abstract

Weekly Cisplatin plus Capecitabine in Metastatic Breast Cancer Patients Heavily Pretreated with both Anthracycline and Taxanes

Cited by 12 publications

References 47 publications

A phase II study of capecitabine plus cisplatin in metastatic triple-negative breast cancer patients pretreated with anthracyclines and taxanes

A phase II study of capecitabine plus cisplatin in metastatic triple-negative breast cancer patients pretreated with anthracyclines and taxanes

Capecitabine and Cisplatin Combination Is an Active and Well-Tolerated Doublet in the Treatment of Metastatic Breast Carcinoma Patients Pretreated with Anthracycline and Taxanes

Platinum-Based Compounds for the Treatment of Metastatic Breast Cancer

Contact Info

Product

Resources

About